Manufacturing scale-up is complete for Avanex Life Sciences' alzheimer's treatment. A Phase I clinical trial of AVANEX 2-73 is set to begin in early 2010.
Some two kilograms of the drug candidate were manufactured by Sweden-based Syntagon, a provider of synthetic organic chemistry services. The contract manufacturer developed a five-step synthetic procedure for production of the compound. In addition, it developed and evaluated analytical methods for the production process.
The compound uses sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease, according to a company announcement.
- here's the announcement